ATE346918T1 - Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide - Google Patents

Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide

Info

Publication number
ATE346918T1
ATE346918T1 AT99928945T AT99928945T ATE346918T1 AT E346918 T1 ATE346918 T1 AT E346918T1 AT 99928945 T AT99928945 T AT 99928945T AT 99928945 T AT99928945 T AT 99928945T AT E346918 T1 ATE346918 T1 AT E346918T1
Authority
AT
Austria
Prior art keywords
relates
arabinose
antisense oligonucleotides
analogues
beta
Prior art date
Application number
AT99928945T
Other languages
English (en)
Inventor
Massad Jose Damha
Michael A Parniak
Anne M Noronha
Christopher Wilds
Gadi Borkow
Dominique Arion
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE346918T1 publication Critical patent/ATE346918T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
AT99928945T 1998-06-19 1999-06-17 Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide ATE346918T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2241361 1998-06-19

Publications (1)

Publication Number Publication Date
ATE346918T1 true ATE346918T1 (de) 2006-12-15

Family

ID=4162575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928945T ATE346918T1 (de) 1998-06-19 1999-06-17 Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide

Country Status (6)

Country Link
US (1) US20090105467A1 (de)
EP (1) EP1088066B1 (de)
AT (1) ATE346918T1 (de)
AU (1) AU4595399A (de)
DE (1) DE69934227T2 (de)
WO (1) WO1999067378A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259706A1 (en) * 2000-05-09 2001-11-20 Reliable Biopharmaceutical, Inc. Polymeric compounds useful as prodrugs
CA2419563C (en) * 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
MXPA04000162A (es) 2001-07-06 2006-05-22 Topigen Pharma Inc Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.
US7132529B2 (en) * 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
ATE416183T1 (de) * 2002-02-01 2008-12-15 Univ Mcgill Oligonukleotide mit alternierenden segmenten und deren verwendungen
US7381820B2 (en) 2003-10-24 2008-06-03 Yamasa Corporation α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside
BRPI0517387A8 (pt) 2004-10-29 2017-07-11 Topigen Pharmaceuticals Inc Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas
EP1971371B1 (de) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
WO2007134451A1 (en) 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
EP2285961A4 (de) 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc Oligonukleotide zur behandlung von entzündungen und neoplastischer zellvermehrung
JP2013520395A (ja) * 2009-02-22 2013-06-06 ケムジーンズ コーポレーション 治療、診断、ｇ‐テトラド形成オリゴヌクレオシド及びアプタマーといった生物学的応用のための新規修飾を取り入れたアラ‐２’‐ｏ‐メチル‐ヌクレオシド、当該ホスホラミダイト及びオリゴヌクレオチドの合成
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
CA2848753C (en) 2011-09-14 2022-07-26 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
EP2797953B1 (de) 2011-12-28 2020-06-03 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
CN104583398A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
JP2016509572A (ja) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Ｂｃｌ２発現の調節による癌の処置のためにバイオマーカーを使用する方法
EP3161159B1 (de) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting von humanem satellit ii (hsatii)
DE102014221734A1 (de) * 2014-10-24 2016-04-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Messvorrichtung und System zur Schmelzkurvenanalyse eines DNA Microarrays, sowie Verwendung eines Fluoreszenzdetektorarrays zur Analyse
WO2018013525A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
US10954255B2 (en) 2017-08-03 2021-03-23 Karl-Franzens-Universitaet Graz Phospholipid analogues
CN112969799A (zh) * 2018-09-26 2021-06-15 奥姆生命科技公司 2′fana修饰的foxp3反义寡核苷酸及其使用方法
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003370A1 (en) * 1988-09-28 1990-04-05 Microprobe Corporation DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
JP3739785B2 (ja) * 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5795726A (en) * 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
US5739119A (en) * 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
CA2419563C (en) * 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
ATE416183T1 (de) * 2002-02-01 2008-12-15 Univ Mcgill Oligonukleotide mit alternierenden segmenten und deren verwendungen

Also Published As

Publication number Publication date
AU4595399A (en) 2000-01-10
US20090105467A1 (en) 2009-04-23
DE69934227D1 (de) 2007-01-11
WO1999067378A1 (en) 1999-12-29
EP1088066A1 (de) 2001-04-04
DE69934227T2 (de) 2007-10-04
EP1088066B1 (de) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE346918T1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
WO2003100017A3 (en) Oligonucleotides having modified nucleoside units
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
DE69734589D1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
DK1163254T3 (da) TRPM-2 antisense-behandling
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
WO2002018641A3 (en) Detection of cyp3a4 and cyp2c9 polymorphisms
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
ATE324440T1 (de) Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
ATE293688T1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2004027056A3 (en) Methods of use for thermostable rna ligases
WO2000008140A3 (en) Antisense oligonucleotides for the inhibition of vegf expression
MXPA03011153A (es) Adn enzimas bcl-2.
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CA2331333A1 (en) Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties